Role of Bisphosphonates in Prostate Cancer Bone Metastases

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Bisphosphonate inhibitors of bone resorption have a variety of positive actions against prostate cancer cells in vitro and in preclinical animal models. In patients, they can reduce skeletal-related events and bone pain, as well as reduce the adverse effects of androgen deprivation therapy on skeletal integrity. The preclinical and clinical data to support this are reviewed here. Further clinical trials are required to determine whether bisphosphonates decrease tumor burden or increase patient survival or quality of life, and whether such adjuvant treatments will be cost-effective.

Original languageEnglish (US)
Pages (from-to)717-723
Number of pages7
JournalSeminars in oncology
Volume30
Issue number5
DOIs
StatePublished - Oct 2003

    Fingerprint

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this